Research into new treatments for metastatic uveal melanoma continues to move forward, and a recently published Phase 1 clinical trial has introduced an encouraging new therapy called DYP688. While the treatment is still in the early stages of development, the study offers hope that more personalized treatment options may become available for people facing this rare form of eye cancer.
DYP688 was created specifically for uveal melanoma tumors that carry GNAQ or GNA11 gene mutations. These genetic changes are found in the vast majority of uveal melanoma cases and play a major role in driving tumor growth. Instead of attacking healthy cells throughout the body, this investigational therapy is designed to seek out melanoma cells by recognizing a protein called PMEL, which is commonly found on their surface. Once attached, the treatment delivers a medication directly into the cancer cell, helping block the signals the tumor depends on to survive.
Researchers enrolled 66 patients with metastatic uveal melanoma and other rare melanomas carrying the same genetic mutations. Most participants had already received previous treatments, making this a group with limited remaining options. The primary goal was to evaluate safety, while also looking for early evidence that the therapy could slow or shrink tumors.
The early findings were promising. Nearly one in five patients experienced a measurable response to treatment, and most participants saw their tumors either shrink or remain stable during the study. Researchers also reported a median progression-free survival of just over seven months, suggesting that DYP688 may help delay cancer growth in many patients.
Equally encouraging was the safety profile. Most side effects were considered manageable and included fatigue, dry mouth, constipation, swelling, and changes in blood calcium levels. Serious treatment-related complications were uncommon, and no participant stopped receiving DYP688 because of side effects.
Although additional clinical trials will be needed before this therapy could become widely available, the study represents another meaningful step toward treatments developed specifically for uveal melanoma. It also highlights the growing momentum behind precision medicine, where therapies are designed around the unique biology of an individual’s cancer rather than using a one-size-fits-all approach.
How A Cure in Sight Can Help
A Cure in Sight is committed to helping patients and families navigate an ocular melanoma diagnosis by providing reliable educational resources, financial assistance programs, patient support, and the latest updates on promising research and clinical trials. As new treatments continue to emerge, our goal is to connect the ocular melanoma community with trusted information and hope for the future.